



DAFTAR PUSTAKA

1. Curatolo, P, Jóźwiak, S, & Nabbout, R. 2012. Management of Epilepsy Associated With Tuberos Sclerosis Complex (TSC): Clinical Recommendations. *European Journal Of Paediatric Neurology*. 16(6):582-586. DOI: [10.1016/j.ejpn.2012.05.004](https://doi.org/10.1016/j.ejpn.2012.05.004).
2. Vries PJ, Wilde L, de Vries MC, Moavero R, Pearson DA & Curatolo P. 2018. A Clinical Update On Tuberos Sclerosis Complex-Associated Neuropsychiatric Disorders (TAND). *Am J Med Genet C Semin Med Genet*.178(3):309-320. DOI: [10.1002/ajmg.c.31637](https://doi.org/10.1002/ajmg.c.31637).
3. Sinaga, F. 2014. Tuberos Sclerosis Complex: Temuan CT Scan Kepala. Yogyakarta: Bagian Radiologi Fakultas Kedokteran Universitas Gadjah Mada
4. Crino PB, Nathanson KL & Henske EP. 2006. The tuberous sclerosis complex. *N Engl J Med*. 355(13):1345-56. DOI: [10.1056/NEJMra055323](https://doi.org/10.1056/NEJMra055323).
5. Amin S, Lux A, Calder N, Laugharne M, Osborne J, & O'callaghan F. 2017. Causes Of Mortality In Individuals With Tuberos Sclerosis Complex. *Dev Med Child Neurol*. 59(6):612-617. DOI: [10.1111/dmcn.13352](https://doi.org/10.1111/dmcn.13352).
6. Curatolo, P., Bombardieri, R., & Jozwiak, S. 2008. Tuberos Sclerosis. *The Lancet*. 372(9639): 657-668. DOI: [10.1016/s0140-6736\(08\)61279-9](https://doi.org/10.1016/s0140-6736(08)61279-9)
7. Rentz A M, Skalicky AM, Liu Z, Wheless JW, Dunn DW & Frost MD. 2015. Tuberos Sclerosis Complex: A Survey Of Health Care Resource Use And Health Burden. *Pediatr Neurol*. 52:435-41.
8. Curatolo P, Verdecchia M, Bombardieri R. 2002. Tuberos sclerosis complex: A Review Of Neurological Spects. *European Journal of Paediatric Neurology*. 6:15-23.
9. Plasticsurgerykey. 2023. Tuberos Sclerosis Complex. <https://plasticsurgerykey.com/tuberos-sclerosis-complex/>. Diakses 5 januari 2023 09:00 PM
10. Sinaga, F. 2014. Tuberos Sclerosis Complex: Temuan CT Scan Kepala. Yogyakarta: Bagian Radiologi Fakultas Kedokteran Universitas Gadjah Mada.
11. Randle, SMM. 2020. *Tuberos sclerosis complex: Genetics, clinical features, and diagnosis*. Official reprint from UpToDate www.uptodate.com ©2020 UpToDate
12. Nabbout, E. B. 2019. Epilepsy In Tuberos Sclerosis Complex: Findings from the TOSCA Study. *Epilepsia Open*. 4:73-84
13. Petrus J. de Vries, LW. 2018. A Clinical Update On Tuberos Sclerosis Complex-Associated Neuropsychiatric Disorders (TAND). *American Journal of Medical Genetics Part C: Seminars in Medical Genetics published by Wiley Periodicals, Inc*, 1-2. 178(3):309-320. DOI: [10.1002/ajmg.c.31637](https://doi.org/10.1002/ajmg.c.31637)
14. Cohen AL, Muder BPF, Prohl AK. 2021. Infantile Spasm in Tuberos Sclerosis Complex: Kesion or Network?. *Epilepsy Currents*. *Ann Neurol*. 89: 726-739. DOI: <https://doi.org/10.1177/15357597211026405>.
15. Singh A, Hadjinicolaou A, Peters JM, Salussolia CL. 2023. Treatment-Resistant Epilepsy and Tuberos Sclerosis Complex: Treatment, Maintenance,



- and Future Directions. *Neuropsychiatr Dis Treat.* 19:733-748. DOI: 10.2147/NDT.S347327.
16. Hake, SDF. 2010. Cutaneous Manifestations of Tuberos Sclerosis. *The Ochsner Journal*, 200-204.
 17. Wan MJ, Chan KL, Jastrzembski, BG & Ali, A. 2019. Neuro-ophthalmological Manifestations Of Tuberos Sclerosis: Current Perspectives. *Eye Brain.* 19;11:13-23. DOI: 10.2147/EB.S186306.
 18. Flanagan N, O'Connor WJ, McCartan B, Miller S, McMenamin J, Watson R. 1997. Developmental Enamel Defects In Tuberos Sclerosis: A Clinical Genetic Marker? *J Med Genet.* **34**: 637–39.
 19. Trnka, P & Kennedy, SE. 2020. *Renal tumors in tuberous sclerosis complex. Pediatric Nephrology*, 36(6), 1427–1438. DOI:10.1007/s00467-020-04775-1.
 20. Nair N, Chakraborty R, Mahajan Z, Sharma A, Sethi SK, Raina R. 2020. Renal Manifestations of Tuberos Sclerosis Complex. *J Kidney Cancer VHL.*7(3):5-19. DOI: 10.15586/jkcvhl.2020.131.
 21. Hinton RB, Prakash A, Romp RL, Krueger DA, Knilans TK. 2014. International Tuberos Sclerosis Consensus Group. Cardiovascular Manifestations Of Tuberos Sclerosis Complex And Summary Of The Revised Diagnostic Criteria and Surveillance And Management Recommendations From The International Tuberos Sclerosis Consensus Group. *J Am Heart Assoc.* 3(6):e001493. DOI: 10.1161/JAHA.114.001493.
 22. Gupta N & Henske, EP. 2018. Pulmonary Manifestations In Tuberos Sclerosis Complex. *Am J Med Genet C Semin Med Genet.* 178(3):326-337. DOI: 10.1002/ajmg.c.31638.
 23. Słowińska M, Kotulska K, Szymańska, S Roberds, SL, Fladrowski, C & Józwiak, S. 2020. Approach To Preventive Epilepsy Treatment In Tuberos Sclerosis Complex And Current Clinical Practice in 23 Countries. *Pediatric Neurology.* DOI:10.1016/j.pediatrneurol.
 24. Curatolo, P., Nabbout, R., Lagae, L., Aronica, E., Ferreira, J. C., Feucht, M., ... Józwiak, S. 2018. Management Of Epilepsy Associated With Tuberos Sclerosis Complex: Updated Clinical Recommendations. *European Journal of Paediatric Neurology.* DOI:10.1016/j.ejpn.2018.05.006
 25. Curatolo P, Cusmai R, Cortesi F, Chiron C, Jambaque I & Dulac O. 1991. Neuropsychiatric Aspects Of Tuberos Sclerosis. *Ann N Y Acad Sci.* **615**: 8–16.
 26. Parthasarathy S, Mahalingam R, Melchiorre J, Harowitz J, Devinsky O. 2021. Mortality in Tuberos Sclerosis Complex. *Epilepsy Behav.* 121(Pt A):108032. DOI: 10.1016/j.yebeh.2021.108032.
 27. Vries PJ, Whittemore VH, Leclezio L, Byars AW, Dunn D, Ess KC, Hook D, King BH, Sahin M & Jansen A. 2015. Tuberos sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist. *Pediatr Neurol.* 52(1):25-35. DOI: 10.1016/j.pediatrneurol.2014.10.004.
 28. Bertoli S, Cardinali S, Veggiotti P, Trentani C, Testolin G, Tagliabue A. 2006. Evaluation of Nutritional Status In Children With Refractory Epilepsy. *Nutr J.*5:14. DOI: 10.1186/1475-2891-5-14.



29. Eatock, J & Baker, GA. 2007. Managing Patient Adherence And Quality Of Life In Epilepsy. *Neuropsychiatr Dis Treat.* 3(1):117-31. DOI: 10.2147/ndt.2007.3.1.117.
30. Zafar A, Shahid R, Nazish S, Aljaafari D, Alkhamis FA, Alsalman S, Msmar AH, Abbasi B, Alsulaiman AA, Alabdali M. 2019. Nonadherence to Antiepileptic Medications: Still a Major Issue to be Addressed in the Management of Epilepsy. *J Neurosci Rural Pract.* 10(1):106-112. DOI: 10.4103/jnrp.jnrp_136_18.
31. Curatolo P, Specchio N, Aronica E. Advances in the genetics and neuropathology of TSC: edging closer to targeted therapy. *Lancet Neurol* 2022;21:843-56
32. Curatolo P, Cusmai R, Cortesi F, Chiron C, Jambaque I, Dulac O. 2015. Neuropsychiatric aspects of tuberous sclerosis. *Ann N Y Acad Sci* 1991; **615**: 8–16
33. Ozwiak S, Schwartz RA, Janniger CK, Bielicka-Cymerman J. 2000. Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients. *J Child Neurol* **15**: 652–59.
34. Sancak O, Nellist M, Goedbloed M, Elfferich P, Wouters C, Maat-Kievit A, Zonnenberg B, Verhoef S, Halley D, van den Ouweland A. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype--phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. *Eur J Hum Genet.* 2005 Jun;13(6):731-41. doi: 10.1038/sj.ejhg.5201402. PMID: 15798777.
35. Langkau N, Martin N, Brandt R, Zügge K, Quast S, Wiegele G, Jauch A, Rehm M, Kuhl A, Mack-Vetter M, Zimmerhackl LB, Janssen B. TSC1 and TSC2 mutations in tuberous sclerosis, the associated phenotypes and a model to explain observed TSC1/ TSC2 frequency ratios. *Eur J Pediatr.* 2002 Jul;161(7):393-402. doi: 10.1007/s00431-001-0903-7. Epub 2002 Jun 8. PMID: 12111193
36. Wang MX, Segaran N, Bhalla S, Pickhardt PJ, Lubner MG, Katabathina VS, Ganeshan D. 2001. Tuberous Sclerosis: Current Update. *RadioGraphics.* 41(7): 1992-2010. DOI: <https://doi.org/10.1148/rg.2021210103>
37. McDonald, N. M., Varcin, K. J., Bhatt, R., Wu, J. Y., Sahin, M., Nelson, C. A., & Jeste, S. S. (2017). *Early Autism Symptoms In Infants With Tuberous Sclerosis Complex.* *Autism Research.* 10(12): 1981–1990. DOI:10.1002/aur.1846.
38. Krueger DA, Northup H, Tuberous I. (2012) Pediatric Neurology Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference1.2013;49
39. Flanagan N, O'Connor WJ, McCartan B, Miller S, McMenemy J, Watson R. (1997). Developmental enamel defects in tuberous sclerosis: a clinical genetic marker? *J Med Genet*; **34**: 637–39.
40. Bader RS, Chitayat D, Kelly E, et al. (2003). Fetal rhabdomyoma: prenatal diagnosis, clinical outcome, and incidence of associated tuberous sclerosis complex. *J Pediatr*; **143**: 620–24.



41. O'Callaghan F.J., Noakes M.J., Martyn C.N., Osborne JP. (2004). An epidemiological study of renal pathology in tuberous sclerosis complex. *BJU Int*; **94**: 853–57.
42. Ding Y, Wang J, Zhou Y, Yu L, Zhang L, Zhou S, Wang Y. (2020). Quality of life in children with tuberous sclerosis complex: A pediatric cohort study. *CNS Neurosci Ther*. 2021 Mar;27(3):280-288. doi: 10.1111/cns.13473. Epub 2020 Nov 23. PMID: 33225634; PMCID: PMC7871787.
43. Tye C, Mcewen FS, Liang H, Underwood L, Woodhouse E, Barker ED, Sheerin F, Yates JRW, Bolton PF. (2000). Long-term cognitive outcomes in tuberous sclerosis complex. *Dev Med Child Neurol*. 2020 Mar;62(3):322-329. doi: 10.1111/dmcn.14356. Epub 2019 Sep 19. PMID: 31538337; PMCID: PMC7027810.
44. Capal JK, Bernardino-Cuesta B, Horn PS, Murray D, Byars AW, Bing NM, Kent B, Pearson DA, Sahin M, Krueger DA.(2017). Influence of seizures on early development in tuberous sclerosis complex. *Epilepsy Behav*. 2017 May;70(Pt A):245-252. doi: 10.1016/j.yebeh.2017.02.007. Epub 2017 Apr 28. PMID: 28457992; PMCID: PMC5497719.
45. Jin, N., Shuja, S., Monteiro, C., Makary, R.(2009). *Tuberous Sclerosis Complex with Diffuse Cytomegalovirus Fetal Infection: Case Report and Review of the Literature*. The Internet Journal of Pediatrics and Neonatology. Volume 11 Number 2.
46. Forte, E., Zhang, Z., Thorp, E. B., & Hummel, M. (2020). *Cytomegalovirus Latency and Reactivation: An Intricate Interplay With the Host Immune Response*. *Frontiers in Cellular and Infection Microbiology*, 10.doi:10.3389/fcimb.2020.00130
47. Madireddy S., Crane J.S. (2023). Hypopigmented Macules. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK563245/>
48. Gipson TT, Gerner G, Srivastava S, Poretti A, Vaurio R, Hartman A, Johnston MV. Early neurodevelopmental screening in tuberous sclerosis complex: a potential window of opportunity. *Pediatr Neurol*. 2014 Sep;51(3):398-402. doi: 10.1016/j.pediatrneurol.2014.04.028. Epub 2014 May 4. PMID: 25160545; PMCID: PMC4196722.
49. Lanzieri TM, Leung J, Caviness AC, Chung W, Flores M, Blum P, Bialek SR, Miller JA, Vinson SS, Turcich MR, Voigt RG, Demmler-Harrison G. Long-term outcomes of children with symptomatic congenital cytomegalovirus disease. *J Perinatol*. 2017 Jul;37(7):875-880. doi: 10.1038/jp.2017.41. Epub 2017 Apr 6. PMID: 28383538; PMCID: PMC5562509.
50. Korndewal MJ, Oudesluys-Murphy AM, Kroes ACM, Vossen ACTM, de Melker HE. Congenital Cytomegalovirus Infection: Child Development, Quality of Life and Impact on Daily Life. *Pediatr Infect Dis J*. 2017 Dec;36(12):1141-1147. doi: 10.1097/INF.0000000000001663. PMID: 28650934.
51. Kalilani L, Sun X, Pelgrims B, Noack-Rink M, Villanueva V. The epidemiology of drug-resistant epilepsy: A systematic review and meta-analysis. *Epilepsia*. 2018;59(12):2179–93.



52. Suzuki, Y., Toribe, Y., Mogami, Y., Yanagihara, K., & Nishikawa, M. (2008). *Epilepsy in patients with congenital cytomegalovirus infection. Brain and Development*, 30(6), 420–424. doi:10.1016/j.braindev.2007.12
53. Korndewal, M. J., Oudesluys-Murphy, A. M., Kroes, A. C. M., Vossen, A. C. T. M., & de Melker, H. E. (2017). *Congenital Cytomegalovirus Infection. The Pediatric Infectious Disease Journal*, 36(12), 1141–1147. doi:10.1097/inf.000000000000016
54. Narayanan, V. (2003). *Tuberous sclerosis complex: genetics to pathogenesis. Pediatric Neurology*, 29(5), 404–409. doi:10.1016/j.pediatrneurol.20
55. Moorman N.J, Cristea I.M, Terhune SS, Rout MP, Chait BT, Shenk T. (2008) Human cytomegalovirus protein UL38 inhibits host cell stress responses by antagonizing the tuberous sclerosis protein complex. *Cell Host Microbe*. 2008 Apr 17;3(4):253-62. doi: 10.1016/j.chom.2008.03.002. PMID: 18407068; PMCID: PMC2759192.
56. Kenji Tanimura *et al.* (2016). Prediction of congenital cytomegalovirus infection in high-risk pregnant women, *Clinical Infectious Diseases*. DOI: [10.1093/cid/ciw707](https://doi.org/10.1093/cid/ciw707)
57. Qian, Z., Xuan, B., Gualberto, N., & Yu, D. (2011). *The Human Cytomegalovirus Protein pUL38 Suppresses Endoplasmic Reticulum Stress-Mediated Cell Death Independently of Its Ability To Induce mTORC1 Activation. Journal of Virology*, 85(17), 9103–9113. doi:10.1128/jvi.00572-11